APVO - Aptevo Therapeutics Inc logo

Aptevo Therapeutics Inc

APVO

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company developing immunotherapeutic candidates using ADAPTIR technology to treat various cancers. Its lead product is mipletamig for acute myelogenous leukemia, with multiple bispecific candidates in trials.

⚕️ Healthcare NASDAQ Listed 2016 $ USD
$1,000 invested 10 years ago →$0today

Score Overview

1 Year
Score—
Net Growth-1.11%
Net TrendShrank
Net Income Consistency—
Rev Growth—
Rev TrendShrank
Revenue Consistency—
5 Years
Score2.2
Net Growth3.87%
Net Trend20%
Net Income Consistency—
Rev Growth-101.79%
Rev TrendNever
Revenue Consistency—
10 Years
Score
Net Growth76.64%
Net Trend40%
Net Income Consistency
Rev Growth-100.60%
Rev Trend30%
Revenue Consistency
All Time
Score
Net Growth76.64%
Net Trend40%
Net Income Consistency
Rev Growth-100.60%
Rev Trend30%
Revenue Consistency

Explore the 2021 public Archive ranking →

Where Aptevo Therapeutics Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. APVO does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-13
$ 1.73—
1 Year2025-10-13
$ 28.80-93.99%
5 Years2021-10-13
$ 1000K-100.00%
10 Years2016-10-13
$ 1000K-100.00%
All Time2016-07-20
$ 1000K-100.00%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM-$ 220K-$ 26M$ 14M
2025$ 0.00-$ 25M$ 21M
2024$ 0.00-$ 24M$ 8M
2023$ 0.00-$ 17M$ 16M
2022$ 3M$ 8M$ 22M
2021$ 12M-$ 27M$ 45M
2020$ 4M-$ 17M$ 39M
2019$ 32M-$ 44M$ 12M
2018$ 23M-$ 53M$ 30M
2017$ 14M$ 6M$ 80M
IPO2016$ 36M-$ 112M$ 54M
APVO - Aptevo Therapeutics Inc logo

Aptevo Therapeutics Inc fundamental performance

Between 2020 and 2025, revenue declined from $ 4M to $ 0.00 and net income went from -$ 17M to -$ 25M. Revenue increased in 0 of those 5 years; net income in 1.

Across Aptevo Therapeutics Inc's full reported history, from 2016 to 2025, revenue declined from $ 36M to $ 0.00 and net income went from -$ 112M to -$ 25M. Revenue increased in 30% of the years measured; net income in 40%.

Aptevo Therapeutics Inc currently holds a 5-year HDB Score of 2.2 out of 10. How the HDB Score is calculated.

Membership

Explore APVO with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,125 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year · Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies